This paper is only available as a PDF. To read, Please Download here.
Abstract
High concentrations of high-density lipoprotein (HDL) are known to decrease the risk
of coronary artery disease. In order to study the underlying cellular mechanisms,
the influence of HDL on the epidermal growth factor (EGF)-induced vascular smooth
muscle cell (VSMC) proliferation was investigated. Approximately 40% of the EGF-induced
increase of the cell DNA synthesis was abolished in the presence of 30 μg/ml HDL.
The EGF-induced dose-dependent (10 pg/ml to 100 ng/ml) increase in DNA synthesis was
blunted by 30 μg/ml HDL. In addition HDL (3–300 μg/ml caused a dose-dependent inhibition
of EGF (20 ng/ml) -induced DNA synthesis, yielding a half maximal effective dose (ED50) of 30 μg/ml Similar experiments with the HDL-protein and HDL-lipid fraction indicated
that the HDL-protein fraction is most probably responsible for the observed inhibiting
effects of HDL. This was confirmed by using purified apolipoprotein (apo) A-I and
apo A-II. Both induced an approximately 80% inhibition of the EGF-induced DNA synthesis.
These results may help to explain the observed beneficial effects of HDL on cardiovascular
diseases that are described in many epidemiological studies.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to AtherosclerosisAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.Circulation. 1989; 79: 8
- High-density lipoprotein: the clinical implications of recent studies.N. Engl. J. Med. 1989; 321: 1311
- HDL cholesterol, triglycerides and coronary heart disease.Curr. Opin. Lipidol. 1990; 1: 330
- A prospective study of cholesterol apolipoproteins, and the risk of myocardial infarction.N. Engl. J. Med. 1991; 325: 373
- Reverse cholesterol transport.Curr. Opin. Lipidol. 1991; 2: 376
- The pathogenesis of atherosclerosis.N. Engl. J. Med. 1986; 314: 488
- Role of growth factor in the formation of blood vessels.Z. Kardiol. 1989; 78: 9
- Replication of smooth muscle cells in vascular disease.Circ. Res. 1986; 58: 427
- The smooth muscle cell II. Growth of smooth muscle in culture and formation of elastic fiber.J. Cell. Biol. 1971; 50: 172
- Stimulation of aortic smooth muscle cell mitogenesis by serotonin.in: Proc. Natl. Acad. Sci. USA. 83. 1986: 674
- A rapid and sensitive method of the quantitation of microgram quantities of protein utilizing the principal of protein-dye binding.Anal. Biochem. 1976; 72: 248
- Separation of plasma lipoproteins by density-gradient ultracentrifugation.Anal. Biochem. 1975; 65: 42
- Advances in the analysis of plasmalipoproteins.Innere Med. 1978; 7: 290
- Some statistical methods useful in circulation research.Circ. Res. 1980; 47: 1
- Serum apoliprotein A-I, A-II and B levels and their discriminative values in relatives of patients with coronary artery disease.Atherosclerosis. 1984; 51: 261
- Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apoliproteins.Br. Med. J. 1981; 282: 1741
- Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.Nature. 1991; 353: 265
- Regression of atherosclerotic lesion by high density lipoprotein plasma fraction in the cholesterol-fed rabbit.J. Clin. Invest. 1990; 85: 1234
Article info
Publication history
Accepted:
December 11,
1992
Received in revised form:
November 27,
1992
Received:
May 26,
1992
Identification
Copyright
© 1993 Published by Elsevier Inc.